Stock CARM CARISMA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Carisma Therapeutics, Inc.

Equities

CARM

US14216R1014

Market Closed - Nasdaq
Other stock markets
 21:00:00 10/05/2024 BST 		5-day change 1st Jan Change
1.48 USD -1.99% Intraday chart for Carisma Therapeutics, Inc. -8.64% -49.49%
05-09 Carisma Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
05-02 Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Carisma Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Carisma Therapeutics Q4 Net Loss Narrows, Revenue Rises; Plans Job Cuts in Q2 -- Shares Decline
MT
Carisma Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Carisma Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
North American Morning Briefing : Inflation Data -2-
DJ
Carisma Therapeutics Obtains FDA Clearance to Study Potential Solid Tumor Therapy
MT
Carisma Therapeutics Announces FDA Clearance of IND Application for CT-0525, a Novel HER2-Targeting CAR-Monocyte
CI
Carisma Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Carisma Therapeutics Inc. Presents Pre-Clinical Proof of Concept for in vivo CAR-M Using mRNA Platform in Collaboration with Moderna at SITC
CI
Carisma Therapeutics Inc. to Present First Results from in Vivo Car-M Collaboration with Moderna at SITC 2023
CI
Carisma Therapeutics, Inc. Announces Latest Data from Phase 1 Clinical Trial of CT-0508 At 8th Annual CAR-TCR Summit
CI
Carisma Therapeutics Announces First Patient Dosed in Phase 1 Study of CT-0508 in Combination with Keytruda(R) (Pembrolizumab) in Patients with Her2 Overexpressing Solid Tumors
CI
Carisma Therapeutics Inc. Provides Pipeline Updates
CI
Carisma Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Carisma Therapeutics Closes Merger with Sesen Bio
AQ
CARISMA Therapeutics Inc. completed the acquisition of Sesen Bio, Inc. from The Vanguard Group, Inc., JEC II Associates, LLC, BML Investment Partners, L.P. managed by BML Capital Management, LLC and others in a reverse merger transaction.
CI
Sesen Bio Gets Shareholders Nod for Carisma Therapeutics Merger, to Pay Special Dividend
MT
Sesen Bio Stockholders Approve Merger with Carisma Therapeutics
BU
SESEN BIO, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)
AQ
Sesen Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CARM Stock
  4. News Carisma Therapeutics, Inc.
  5. Highlights